Clinical Development Process in ICH E5 Environment (1)

Slides:

Advertisements

Similar presentations

1 WORKSHOP 4: KEY COMMENTS FROM THE PANEL DISCUSSION The 3rd Kitasato University - Harvard School of Public Health Symposium Wednesday October 2nd - Thursday.

Advertisements

HOT TOPICS ARCHIVING OR HOW NOT TO DUMP YOUR RUBBISH!

Dr. M. Iwasaki 1 Asian Multinational Clinical Trials - Current Status & Future Direction - Dr.Masaru IWASAKI PR Japan Operations Center Aventis Pharma,

ICH E-5 Overview and Current Topics Mamoru Narukawa.

Neurological Predictors of Huntington’s Disease

4 th Kitasato-Harvard Symposium: Summary and Conclusions Stephen Lagakos Harvard School of Public Health.

Drug Development in Asia – an Industry perspective Stephen UdenPfizer Inc.

K. Shimatani/ K-H Symposium/ October 22-23, What Impact Will Globalization Have on Bridging Studies Katsuyoshi Shimatani J-Clin, Pfizer.

2nd Kitasato-Harvard 23/10/2001 Toward Regional Multi-Centered Trials Daisaku Sato Evaluation and Licensing Division Ministry of Health, Labour and Welfare.

Many Important Issues Covered Current status of ICH E5 and implementation in individual Asian countries Implementation at a regional level (EU) and practical.

ICH Harmonization Eric W. Lewis, MD GlaxoSmithKline October 3 rd, 2002 The Basis of Global Drug Development.

Some Closing Remarks. Scope of Symposium Simultaneous Worldwide Development Strategies & Pharmacogenomics: 6 Sessions –1. Overview: Drs. Yazaki; Fujiwara,

Traditional Process First in Human Single Ascending Dose Multiple Ascending Dose U.S.A. Japan Phase II Phase III NDA in Japan Phase II Phase III NDA in.

GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

Statistical considerations for a multi-regional trial Hiroyuki Uesaka, Ph. D October 28, 2003 Kitasato University-Harvard School of Public Health Symposium.

Tipologie di Audit e loro caratteristiche Riunione sottogruppo GCP-GIQAR 21 Marzo 2006 Francesca Bucchi.

1 Points to Consider of Protocol on Multinational Trial Masaaki Kuwahara, Ph.D. Takeda Chemical Industries, Ltd. The 4th Kitasato-Harvard symposium,

Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.

1 ACI Life Sciences Mergers & Acquisitions – March 12, 2009 ASENT INTERNATIONAL SYMPOSIUM ~ Acceptability of Foreign Data~ February 26, 2011 February 26,

Protocol Complexity as a Factor in Vendor Management Compliance Risk

Points for Discussion Panelists: Drs.Iwasaki, Takahashi, Wood.

Significance of Extrapolation of Foreign Clinical Data to Asian Countries Masahiro Takeuchi Div. of Biostatistics Kitasato University Graduate School The.

BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Solving the Missing Link Between Forecasting and ERP in Clinical Supply Optimization Michelle.

Development of metadata in the National Statistical Institute of Spain Work Session on Statistical Metadata Genève, 6-8 May-2013 Ana Isabel Sánchez-Luengo.

Systems Development Lifecycle Testing and Documentation.

© GEO Secretariat GEO Work Plan 2nd GEOSS Science and Technology Stakeholder Workshop "GEOSS: Supporting Science for the Millennium Development.

Development Process and Testing Tools for Content Standards OASIS Symposium: The Meaning of Interoperability May 9, 2006 Simon Frechette, NIST.

+ EOIS-CaMS DATA MIA EOIS-CaMS Data Management, Integrity and Analysis (Data MIA) Prepared by: Robyn Cook-Ritchie, RCR Consulting ManagementIntegrity Analysis.

Dr. Mike Ferris Clinical Data for JNDA based on Bridging Japanese Data PK/PD data Bridging trial Foreign Data PK/PD data Trial to compare with bridging.

Outline of Japanese Alliance for Climate Change Observation (JACCO) Shin MIYAZAKI ( Office for Coordination of Climate Change Observation (OCCCO), Japan.

Implementation of the E5 Guideline: Status and Next Steps.

Summary of Discussion. l Issues –Practical use of ICH E5 guideline –Simultaneous global drug development.

Advanced and Global Drug Development Techniques: Brigding Strategies and Pharmacogenomics Simltaneous/ Worldwide Development Strategies: Overview Thomas.

Ian Ayres Accountable Officer West Kent Clinical Commissioning Group.

Medical Writing Special Interest Area Community (SIAC) Medical Communications March Workshop 2012 David Clemow SIAC Chair Melissa Ossanna Communications.

© Copyright IBM 2007DIA ERS SIAC Presentation, January 2008 The HL7 RPS and SPL Standards - A High Level View Terry Hardin Sr. IT Architect Emerging Software.

Regulatory Intelligence for the Emerging Markets Lisa Rysso-DeMaggio President, RAQUELIAN Consulting DIA Regulatory Intelligence Working Group, 10 Sep.

The Globalization of Clinical Development Technology - Current Status & NTRM - Sang - Goo Shin, MD. PhD SNU. Coll. Med. February 26, 2003.

CTD Content Management

The Information Professional’s Role in Product Safety

ICH E17 General Principles for Planning and Design of MRCTs

FirstPoint and FirstDoc Application of the DIA EDM Reference Model

Performance in Initiating and Delivering Clinical Research

VALERI meeting Avignon 10/03/2005.

Future Leaders In Research Programme (FLIR) Session 1

Wear and Acceptability Test

مفاهیم بهره وري.

Evaluating health promotion programs

Analytical Method Validation PAI Readiness / Certification

Regulation of Medical Products & Patient Safety- A Narrative Review

Label Name Label Name Label Name Label Name Label Name Label Name

Roles and Functions of CJK NGN WG for NGN Standardization Chae-Sub LEE

Sandra M. Foote Senior Advisor, Chronic Care Improvement June 23, 2005

Network support for researchers Jonathan Sheffield, Chief Executive

Global Resources Network: Association for Asian Studies Meeting

UK-wide study (lead R&D office in Scotland)

Test Process “V” Diagram

C.2.10 Sample Questions.

Domestic Data Foreign Data PMS Pivotal dose-response IIa PK / PD

Wear and Acceptability Test

Grants Management Solution Suite (GMSS)

C.2.8 Sample Questions.

C.2.8 Sample Questions.

Industry WG Update Jonathan Pearce

Brief DFT Report (1/11/18) Gary Berg-Cross

Wear and Acceptability Test

NRS R&D permissions process Scottish sites only, multicentre

PROCESS VALIDATION - ACTUAL REGULATION, PERFORMING AND INSPECTION

Presentation transcript:

Clinical Development Process in ICH E5 Environment (1) Current status ; Classical bridging Bridging study in PIIb (DFS) Aiming skipping PIII Most efficient in legacy products Only acceptable on prospective planning Need to reduce the initial GAP for simultaneous filing 2002/10/03 Dr.Iwasaki / 3rd K-H Symposium

Clinical Development Process in ICH E5 Environment (2) Current Target ; From Bridging to Global Study P.I ; one site study / one protocol with two sites PIIa ; Pharmacological bridging Participation in Global studies for simultaneous filing 1, Conditions for starting PI 2, Validity of surrogate marker in PIIa 3, Integrated Global development plan with Japan input 4, Regional modification of the study protocol 5, Sample size - Only from Japan, or from Asian region 2002/10/03 Dr.Iwasaki / 3rd K-H Symposium

Clinical Development Process in ICH E5 Environment (3) Future Target ; Global Drug Development Core data from pivotal global studies Regional studies for all sites Simultaneous filing with same documents Regional adjustment of labeling Need to consider Integrated Global Review 2002/10/03 Dr.Iwasaki / 3rd K-H Symposium